Trump Action Archive

A searchable record of documented actions, compiled weekly from public sources.

1 event matching

Export CSVResearcher JSONAnalyst Newest first · Oldest first
Filtering Week: Week 71 × Attack target: Science × Trait: Wealth buys not only speech, but law × Clear all ☆ Save this search
Tier 1 carried by a primary record Corroborated 2+ independent news desks Every result is verified and democracy-related.

Open an event to see its evidence. Attack and trait tags link to their definitions

May 26, 2026 Frederick Cooper donated $1 million to Trump's super PAC days after his company received a serious FDA enforcement letter Tier 1 · Primary Economic Structure

A pharmaceutical executive's large political donation followed closely on a threatening regulatory action against his company, raising quid pro quo concerns.

Primary sourceA record that carries the claim alone
Supporting reportingSurfacings — do not carry alone

Supporting reports

  • FDA sends serious enforcement letter to pharmaceutical company; CEO donates $1 million to Trump super PAC days later — On May 26, the FDA sent a letter to pharmaceutical company QOL Medical containing serious allegations that could threaten the company's existence. Days later, QOL Medical CEO Frederick Cooper donated $1 million to MAGA Inc., Trump's super PAC. The timing and sequence raise questions about whether the donation was made in response to the regulatory threat or as an attempt to influence the agency's enforcement action.
  • FDA sends warning letter to QOL Medical for false drug advertising — On May 26, 2026, the FDA sent a warning letter to QOL Medical accusing the pharmaceutical company of using "false or misleading" advertising to promote Sucraid, a drug for treating congenital sucrase-isomaltase deficiency (CSID). The FDA alleged that QOL Medical's marketing materials encouraged doctors to prescribe Sucraid for patients with IBS-like symptoms (gas, bloating, diarrhea, nausea), despite the drug being unable to treat IBS or its symptoms. The FDA determined QOL Medical violated the Federal Food, Drug, and Cosmetic Act's prohibition on drug misbranding. The letter required QOL Medical to respond within 15 working days.
Verified: Tier 1 primary record Week 71 – 2026-05-23–2026-05-29 wk71_ES_012